Frederik Stevenaert
Overview
Explore the profile of Frederik Stevenaert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
339
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Venken K, Jarlborg M, Stevenaert F, Malfait T, Vlieghe C, Abraham Y, et al.
Ann Rheum Dis
. 2024 Nov;
PMID: 39521450
Objectives: Smoking has been associated with an increased risk of developing rheumatoid arthritis (RA) in individuals carrying shared epitope (SE) HLA-DRB1 alleles. Yet, little is known about the regional and...
2.
Villellas C, Stevenaert F, Remmerie B, Andries K
Antimicrob Agents Chemother
. 2024 Mar;
68(4):e0127523.
PMID: 38470194
Multidrug-resistant tuberculosis (MDR-TB) patients not cured at the time of stopping treatment are exposed to Minimum Inhibitory Concentration (MIC) and sub-MIC levels for many months after discontinuing bedaquiline (BDQ) or...
3.
Cetin M, Pinamonti V, Schmid T, Boschert T, Mellado Fuentes A, Kromer K, et al.
Sci Adv
. 2024 Feb;
10(5):eadk3060.
PMID: 38306432
Effective, unbiased, high-throughput methods to functionally identify both class II and class I HLA-presented T cell epitopes and their cognate T cell receptors (TCRs) are essential for and prerequisite to...
4.
Turcinov S, af Klint E, Van Schoubroeck B, Kouwenhoven A, Mia S, Chemin K, et al.
Arthritis Rheumatol
. 2022 Nov;
75(5):673-684.
PMID: 36409582
Objective: CD4+ T cells are implicated in rheumatoid arthritis (RA) pathology from the strong association between RA and certain HLA class II gene variants. This study was undertaken to examine...
5.
Lim J, Jones C, Loh T, Ting Y, Zareie P, Loh K, et al.
Sci Immunol
. 2021 Apr;
6(58).
PMID: 33863750
Individuals expressing HLA-DR4 bearing the shared susceptibility epitope (SE) have an increased risk of developing rheumatoid arthritis (RA). Posttranslational modification of self-proteins via citrullination leads to the formation of neoantigens...
6.
Casneuf T, Adams 3rd H, van de Donk N, Abraham Y, Bald J, Vanhoof G, et al.
Leukemia
. 2020 May;
35(2):573-584.
PMID: 32457357
CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1/2 studies GEN501/SIRIUS revealed a novel immunomodulatory mechanism of action (MOA) of daratumumab that enhanced the immune...
7.
Adams 3rd H, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, et al.
Cytometry A
. 2018 Dec;
95(3):279-289.
PMID: 30536810
Daratumumab is a CD38-targeted human monoclonal antibody with direct anti-myeloma cell mechanisms of action. Flow cytometry in relapsed and/or refractory multiple myeloma (RRMM) patients treated with daratumumab revealed cytotoxic T-cell...
8.
Smets T, Stevenaert F, Adams 3rd H, Vanhoof G
Methods Mol Biol
. 2018 May;
1792:47-54.
PMID: 29797251
Mass cytometry has emerged as a new state-of-the-art technology that enables in-depth characterization of cellular populations and functions at a single cell resolution. We describe the application of this technology...
9.
Guo J, Buist A, Soares A, Callaerts K, Calafate S, Stevenaert F, et al.
J Biol Chem
. 2016 Apr;
291(25):13175-93.
PMID: 27129267
Filamentous tau aggregates, the hallmark lesions of Alzheimer disease (AD), play key roles in neurodegeneration. Activation of protein degradation systems has been proposed to be a potential strategy for removing...
10.
Banerjee A, Stevenaert F, Pande K, Haghjoo E, Antonenko S, Gorman D, et al.
Infect Immun
. 2010 Jan;
78(3):1353-63.
PMID: 20065029
Paired immunoglobulin-like type 2 receptors (PILRs) inhibitory PILRalpha and activating PILRbeta are predominantly expressed on myeloid cells. Their functions in host defense and inflammation are largely unknown, and in this...